These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2107055)

  • 1. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. II. Expulsions and removals. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation.
    Koetsawang S; Ji G; Krishna U; Cuadros A; Dhall GI; Wyss R; Rodriquez la Puenta J; Andrade AT; Khan T; Kononova ES
    Contraception; 1990 Feb; 41(2):125-41. PubMed ID: 2107055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. I. Contraceptive efficacy and side effects. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation.
    Koetsawang S; Ji G; Krishna U; Cuadros A; Dhall GI; Wyss R; Rodriquez la Puenta J; Andrade AT; Khan T; Kononova ES
    Contraception; 1990 Feb; 41(2):105-24. PubMed ID: 2107054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. IV. Bleeding patterns. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation.
    Koetsawang S; Ji G; Krishna U; Cuadros A; Dhall GI; Wyss R; Rodriquez la Puenta J; Andrade AT; Khan T; Konova ES
    Contraception; 1990 Feb; 41(2):151-67. PubMed ID: 2107057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. III. The relationship between pregnancy rate and body weight. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation.
    Koetsawang S; Ji G; Krishna U; Cuadros A; Dhall GI; Wyss R; Rodriquez la Puenta J; Andrade AT; Khan T; Kononova ES
    Contraception; 1990 Feb; 41(2):143-50. PubMed ID: 2107056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical performance of a levonorgestrel-releasing intracervical contraceptive device during the first year of use.
    Ratsula K
    Contraception; 1987 Dec; 36(6):659-66. PubMed ID: 3128429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and acceptability of a low-dose levonorgestrel intravaginal ring for contraception in a UK cohort.
    Elder MG; Lawson JP; Elstein M; Nuttall ID
    Contraception; 1991 Feb; 43(2):129-37. PubMed ID: 1904020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study on the efficacy and acceptability of two contraceptive pills administered by the vaginal route: an international multicenter clinical trial.
    Coutinho EM; de Souza JC; da Silva AR; de Acosta OM; Alvarez F; Brache V; Garza Flores J; Vasquez-Estrada L; Santo R; Bassol S
    Clin Pharmacol Ther; 1993 Jan; 53(1):65-75. PubMed ID: 8422744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immediate postpartum intrauterine device and implant program outcomes: a prospective analysis.
    Eggebroten JL; Sanders JN; Turok DK
    Am J Obstet Gynecol; 2017 Jul; 217(1):51.e1-51.e7. PubMed ID: 28342716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for and outcomes of ring expulsions with a 1-year contraceptive vaginal system.
    Plagianos MG; Ramanadhan S; Merkatz RB; Brache V; Friedland BA; Haddad LB
    Am J Obstet Gynecol; 2024 May; 230(5):548.e1-548.e8. PubMed ID: 38295968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microdose intrauterine levonorgestrel for contraception. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction: Task Force on Intrauterine Devices for Fertility Regulation.
    Contraception; 1987 Apr; 35(4):363-79. PubMed ID: 2887401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canadian Contraception Consensus (Part 3 of 4): Chapter 7--Intrauterine Contraception.
    Black A; Guilbert E; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman W; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; Mansouri S
    J Obstet Gynaecol Can; 2016 Feb; 38(2):182-222. PubMed ID: 27032746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study.
    Sivin I; el Mahgoub S; McCarthy T; Mishell DR; Shoupe D; Alvarez F; Brache V; Jimenez E; Diaz J; Faundes A
    Contraception; 1990 Oct; 42(4):361-78. PubMed ID: 2124179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A collaborative study of the progesterone intrauterine device (Progestasert). The World Health Organization Task Force on Methods for the Regulation of Implantation.
    Newton J; Szontagh F; Lebech P; Rowe P
    Contraception; 1979 Jun; 19(6):575-89. PubMed ID: 487808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of menstrual bleeding patterns among women using natural and hormonal methods of contraception. I. Regional variations.
    Belsey EM; Peregoudov S
    Contraception; 1988 Aug; 38(2):227-42. PubMed ID: 2971507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ins and outs of drug-releasing vaginal rings: a literature review of expulsions and removals.
    Boyd P; Merkatz R; Variano B; Malcolm RK
    Expert Opin Drug Deliv; 2020 Nov; 17(11):1519-1540. PubMed ID: 32684013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twelve-month contraceptive continuation and repeat pregnancy among young mothers choosing postdelivery contraceptive implants or postplacental intrauterine devices.
    Cohen R; Sheeder J; Arango N; Teal SB; Tocce K
    Contraception; 2016 Feb; 93(2):178-83. PubMed ID: 26475368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrauterine devices: an effective alternative to oral hormonal contraception.
    Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical investigation of low dose levonorgestrel releasing vaginal ring].
    Gao J
    Shengzhi Yu Biyun; 1987 Aug; 7(3):62-5. PubMed ID: 12315174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
    Wildemeersch D; Janssens D; Andrade A
    Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Menstrual blood loss with use of a vaginal ring releasing 20 micrograms levonorgestrel per day. World Health Organization. Task force on long-acting systemic agents for fertility regulation.
    Contraception; 1993 May; 47(5):455-68. PubMed ID: 8513672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.